Alerta

Fresenius Medical Care AG (FMS)

NYSE: FMS · Precio en tiempo real · USD

23.50

-0.27 (-1.14%)

Al cierre: Aug 17, 2026, 3:59 PM

23.86

+1.49%

Premercado: 5:00 AM

-1.14% (1D)

Precio de compra	23.7
Capitalización de mercado	12.51B
Ingresos (TTM)	19.43B
Beneficio neto (TTM)	937.78M
Beta	0.84
EPS (TTM)	1.89
Ratio PER (TTM)	12.43
Adelante PE	6.48
P/B (TTM)	0.86
P/S (TTM)	0.64
Earnings Date	Nov 3, 2026

Precio de venta	n/a
Volumen	492,004
Volumen medio (20D)	734,881
Abierto	23.77
Anterior Cerrar	23.77
Rango del día	23.50 - 23.86
Rango de 52 semanas	20.02 - 27.64
analista	Hold
Precio objetivo	25.17 (7.11%)
Dividendos	$0.87 (3.67%)
Fecha ex dividendo	22 may 2026

Acerca de FMS

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient'...

[Leer más]

Industria Medical Care Facilities

Sector Healthcare

IPO Fecha Sep 17, 1996

Empleados 107,226

Bolsa de Valores NYSE

Símbolo bursátil FMS

Sitio web https://www.freseniusmedicalcare.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Fresenius Medical Care fueron 19.63B, un aumento de 1.51% en comparación con 19.34B del año anterior. Las ganancias fueron 978.37M, un aumento de 81.88%.

Estados financieros

Pronóstico del analista

Según las calificaciones de los analistas de 7, la calificación promedio de las acciones de FMS es "Hold". El pronóstico del precio de las acciones a 12 meses es 25.17, que es Potencial alcista de 7.11% del último precio.

Previsiones bursátiles

Sorpresa de resultados

Fresenius Medical Care ha publicado sus resultados trimestrales en Aug 3, 2026:

Ingresos de n/a falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de 0.56 supera las estimaciones en 0.06, con 21.74% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Fresenius Medical Care AG publique sus resultados el Nov 3, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

6 días hace · Motley Fool

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

U.S. referral execution gap offset by strong margin expansion and transformation savings.

1 semana hace · Zacks

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

1 semana hace · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and ...

1 semana hace · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns

Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the ch...

1 semana hace · Simply Wall St.

Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, res...

Página 1 de 2

Fresenius Medical Care AG (FMS)